Context Therapeutics Inc. (CNTX) Monday said it has submitted Investigational New Drug (IND) application to the U.S. Food and Drug Administration to start a first-in-human clinical study of its drug candidate CTIM-76.
The company plans to initiate a Phase 1 study to evaluate CTIM-76 in patients with gynecologic and testicular cancers.
For comments and feedback: editorial@rttnews.com